The DOI matches its Crossref record.
IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity.
Abstract
Human peripheral blood-derived eosinophils were assessed for their viability, density, and functional properties after 7 days of culture with purified mouse IL-5 and mouse 3T3 fibroblasts. Whereas none of the eosinophils remained viable after 7 days of culture in the absence of IL-5, 38 +/- 12% and 61 +/- 14% (n = 6, mean +/- SD) of the eosinophils survived in the presence of 1 pM IL-5 alone or 1 pM IL-5 in the presence of 3T3 fibroblasts, respectively (p less than 0.05). Direct contact between the fibroblasts and the eosinophils was not needed for this enhanced IL-5-dependent viability. After 7 days, 66 +/- 7% (n = 6) of the cocultured eosinophils were viable when the two cell types were separated by a 0.4-microns filter. As assessed by density-gradient centrifugation after 7 days of IL-5 exposure, all of the original normodense eosinophils became hypodense. The time course of this conversion was accelerated by the presence of 3T3 fibroblasts. Enhanced helminthic cytotoxicity was maintained by the 7-day cultured eosinophils only if they had been cocultured with fibroblasts. Eosinophils killed 10 +/- 11% (n = 5), 48 +/- 17%, and 31 +/- 15% of the larvae when they were cultured for 7 days in IL-5 alone, in IL-5 in direct contact with 3T3 fibroblasts, or in IL-5 with filter separation of the fibroblasts and the eosinophils, respectively. The ability of IL-5 to induce progenitor cells to differentiate selectively into eosinophils, and of 3T3 fibroblasts to facilitate the IL-5-mediated conversion of normodense eosinophils to hypodense eosinophils with increased viability and antibody-dependent cytotoxicity suggests a role for both hematopoietic and tissue factors in determining the presence and pathobiologic function of activated hypodense eosinophils in patients with hypereosinophilic conditions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Lewis (1990) · doi:10.1056/nejm199009063231006 · Cited by 1,200
The idiopathic hypereosinophilic syndrome
Weller, P., & Bubley, G. (1994) · Blood · doi:10.1182/blood.v83.10.2759.2759 · Cited by 929
Borish, L. C., & Steinke, J. W. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.108 · Cited by 879
Flood-Page, P., Menzies-Gow, A., Phipps, S., Ying, S., Wangoo, A., Ludwig, M. S., Barnes, N., Robinson, D., & Kay, A. B. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17974 · Cited by 841
Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808
The Immunobiology of Eosinophils
Flier, J. S., Underhill, L. H., & Weller, P. F. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104183241607 · Cited by 635
T cells and eosinophils in the pathogenesis of asthma
Corrigan, C. J., & Kay, A. B. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90026-4 · Cited by 570
Immunologic messenger molecules: Cytokines, interferons, and chemokines
Commins, S. P., Borish, L., & Steinke, J. W. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2009.07.008 · Cited by 479
Fundamental signals that regulate eosinophil homing to the gastrointestinal tract
Mishra, A., Hogan, S. P., Lee, J. J., Foster, P. S., & Rothenberg, M. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6560 · Cited by 400
Self-citationPharmacology of the Eosinophil
Giembycz, M. A., & Lindsay, M. A. (1999) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01404-2 · Cited by 351
Rothenberg, M. E., Luster, A. D., & Leder, P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8960 · Cited by 345
Self-citationA new dawn for eosinophils in the tumour microenvironment
Grisaru-Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 302
Menzies-Gow, A., Flood-Page, P., Sehmi, R., Burman, J., Hamid, Q., Robinson, D. S., Kay, A. B., & Denburg, J. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2003.1382 · Cited by 276
Sedgwick, J. B., Calhoun, W. J., Gleich, G. J., Kita, H., Abrams, J. S., Schwartz, L. B., Volovitz, B., Ben-Yaakov, M., & Busse, W. W. (1991) · American Review of Respiratory Disease · doi:10.1164/ajrccm/144.6.1274 · Cited by 275
Corrigan, C. J., Haczku, A., Gemou-Engesaeth, V., Doi, S., Kikuchi, Y., Takatsu, K., Durham, S. R., & Kay, A. B. (1993) · American Review of Respiratory Disease · doi:10.1164/ajrccm/147.3.540 · Cited by 263
Xue, L., Gyles, S. L., Wettey, F. R., Gazi, L., Townsend, E., Hunter, M. G., & Pettipher, R. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.10.6531 · Cited by 261
Update on eosinophilic granulomatosis with polyangiitis
Furuta, S., Iwamoto, T., & Nakajima, H. (2019) · Allergology International · doi:10.1016/j.alit.2019.06.004 · Cited by 258
Emerging Roles for Eosinophils in the Tumor Microenvironment
Reichman, H., Karo-Atar, D., & Munitz, A. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.002 · Cited by 116
“IL-5 is the most specific cytokine to the eosinophil lineage and is responsible for their selective expansion [15], release from the bone marrow into the peripheral circulation [16], and survival [17].”
BackgroundChakir, J., Laviolette, M., Turcotte, H., Boutet, M., & Boulet, L.-P. (2000) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2000.110100 · Cited by 88
Metadata
- Authors
- Rothenberg, M. E., Petersen, J., Stevens, R. L., Silberstein, D. S., McKenzie, D. T., Austen, K. F., & Owen, W. F.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1989-10-01
- Volume
- 143
- Issue
- 7
- Pages
- 2311-2316
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2099865106
- Cited by
- 282
- References
- 0
- FWCI
- 11.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.